Coagulation disorders

R. E. Scharf

doi:10.1055/s-0037-1619820

Hämostaseologie, Table of Contents

Hamostaseologie 2015; 35(04): 301-302
DOI: 10.1055/s-0037-1619820

Editorial

Schattauer GmbH

Coagulation disorders

Recent lessons from clinical conditionsGerinnungsstörungenJüngste Lehren aus Krankheitsbildern

R. E. Scharf Prof.

¹Dept. of Experimental and Clinical Hemostasis, Hemotherapy and Transfusion Medicine, and Hemophilia Comprehensive Care Center, Heinrich Heine University Medical Center, Düsseldorf; Biological Medical Research Center, Heinrich Heine University, Düsseldorf

› Author Affiliations

Abstract

Full Text

References

References
1 New Testament. Revelation of St. John. 5: 1.
2 Scharf RE, Bode C. 59th Annual Congress of the Gesellschaft für Thrombose-und Hämostaseforschung e.V. Message from the Congress Presidents. Hämostaseologie 2015; 35: 3-5.
3 Scharf RE. Platelet pathology and vascular medicine. Hämostaseologie 2015; 35: 9.
4 Scharf RE. Von Willebrand factor, hemostasis and inflammation. Hämostaseologie 2015; 35: 209-210.
5 Medcalf RL. What drives “fibrinolysis”. Hämostaseologie 2015; 35: 303-310.
6 Tiede A, Scharf RE, Dobbelstein C, Werwitzke S. Management of acquired haemophilia A. Hämostaseologie 2015; 35: 311-318.
7 Knoebl P, Marco P, Baudo F. et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Hemophilia Registry (EACH2). J Thromb Haemost 2012; 10: 622-631.
8 Tiede A, Klamroth R, Scharf RE. et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125: 1091-1097.
9 Hisada Y, Geddingd JE, Ay C, Mackman N. Venous thrombosis and cancer: from mouse models and clinical trials. J Thromb Haemost 2015; 13: 1372-1382.
10 Langer F. Hämostaseologische Aspekte in der Onkologie. Hämostaseologie 2015; 35: 152-164.
11 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122: 1712-1723.
12 Ay C, Pabinger I. VTE risk assessment in cancer. Who needs prophylaxis and who does not? Hämostaseologie 2015; 35: 319-324.
13 Mammadova-Bach E, Mangin P, Lanza F, Gachet C. Platelets in cancer. From basic research to therapeutic implications. Hämostaseologie 2015; 35: 325-336.
14 Labberton L, Kenne E, Renné T. New agents for thromboprotection. A role for factor XII and XIIa inhibition. Hämostaseologie 2015; 35: 338-350.
15 Bosch J, Eikelboom JW. Management of bleeding with oral anticoagulants in patients with atrial fibrillation. Hämostaseologie 2015; 35: 351-357.
16 Heckmann M, Thermann H, Heckmann F. Rivaroxaban versus high-dose nadroparin for the thromboprophylaxis after hip or knee arthroplasty. Hämostaseologie 2015; 35: 358-363.
17 Tiede A, Klamroth R, Oldenburg J. Turoctocog alfa (recombinant factor VIII): manufacturing, characteristics and clinical trial results. Hämostaseologie 2015; 35: 364-371.
18 Sanidas EA, Viniou NA, Diamantopoulos P. et al. Heparin-induced thrombocytopenia. Contemporary therapeutic approaches in light of the new oral anticoagulants. Hämostaseologie 2015; 35: 372-375.